Information Provided By: 
Fly News Breaks for September 20, 2018
ACAD
Sep 20, 2018 | 14:21 EDT
After the FDA completed its formerly announced review of Nuplazid and concluded that the drug's benefits outweigh its risks and its label does not need to be changed, Stifel analyst Paul Matteis called the conclusion "as good as one could expect." The news "completely removes the worst case scenario off the table," but Matteis still worries that the negative perception caused by the CNN articles that "sensationalized" the death rate of Nuplazid patients may take time to overcome. The analyst maintains a Hold rating on Acadia shares.
News For ACAD From the Last 2 Days
There are no results for your query ACAD
